Singular Health Group Ltd (AU:SHG)
ASX:SHG
Top Page
Singular Health Group Ltd
(Sydney:SHG)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.20
▼(-23.85% Downside)
Action:ReiteratedDate:01/10/26
The score is driven primarily by weak financial performance (large losses, shrinking revenue in 2025, and ongoing cash burn) despite an improved latest-period balance sheet. Technicals add modest pressure due to a downtrend below major moving averages, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Low leverage
The company's 2025 balance sheet shows zero debt and lower leverage, reducing near‑term refinancing and interest risk. A low debt load gives management more flexibility to prioritize product development or strategic investments without immediate debt servicing pressure.
Negative Factors
Sustained unprofitability
Persistent multi‑year losses and an extremely negative net margin indicate the core business is not yet profitable. Over the medium term this undermines internal capital generation, limits reinvestment capacity, and requires external funding to sustain operations unless margins materially improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The company's 2025 balance sheet shows zero debt and lower leverage, reducing near‑term refinancing and interest risk. A low debt load gives management more flexibility to prioritize product development or strategic investments without immediate debt servicing pressure.
Read all positive factors
Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$63.14M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.01
Shares Outstanding315,685,300
10 Day Avg. Volume889,327
30 Day Avg. Volume1,029,223
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)6.82
Price to Sales (P/S)160.16
P/FCF Ratio-37.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Singular Health Group Ltd Business Overview & Revenue Model
Company Description
Singular Health Group Ltd, a medical technology company, develops and commercializes volumetric rendering platform (VRP) for the 3D and virtual reality (VR) visualization of anatomy using standard radiological imagery. It offers 3Dicom Viewer, a c...
How the Company Makes Money
null...
Singular Health Group Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.53K | 557.61K | 934.07K | 28.12K | 54.03K | 193.64K |
| Gross Profit | -2.01M | -86.22K | 516.36K | -3.58M | -2.11M | -1.62M |
| EBITDA | -8.14M | -6.27M | -2.58M | -4.52M | -5.65M | -2.86M |
| Net Income | -7.43M | -6.38M | -4.92M | -5.39M | -5.99M | -4.46M |
Balance Sheet | ||||||
| Total Assets | 12.55M | 14.21M | 2.35M | 3.00M | 2.14M | 5.43M |
| Cash, Cash Equivalents and Short-Term Investments | 11.06M | 13.68M | 1.45M | 691.51K | 1.14M | 4.14M |
| Total Debt | 113.71K | 0.00 | 218.45K | 2.51M | 85.66K | 147.59K |
| Total Liabilities | 856.60K | 1.11M | 909.59K | 2.94M | 391.50K | 345.10K |
| Stockholders Equity | 11.69M | 13.10M | 1.44M | 61.89K | 1.75M | 5.08M |
Cash Flow | ||||||
| Free Cash Flow | -4.38M | -2.37M | -2.51M | -2.49M | -2.92M | -2.22M |
| Operating Cash Flow | -4.23M | -2.34M | -2.44M | -2.46M | -2.91M | -1.91M |
| Investing Cash Flow | -8.49M | 88.14K | -3.56K | -635.21K | -17.12K | -610.57K |
| Financing Cash Flow | 6.36M | 14.48M | 3.21M | 2.65M | -69.25K | 6.52M |
Singular Health Group Ltd Technical Analysis
Negative
0.26
Price Trends
0.24
Negative
0.25
Negative
0.29
Negative
Market Momentum
>-0.01
Positive
35.17
Neutral
2.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SHG, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.24, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.17 is Neutral, neither overbought nor oversold. The STOCH value of 2.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:SHG.
Singular Health Group Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$130.27M | 26.51 | 4.37% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$59.93M | -6.28 | -23.86% | ― | 15.99% | 22.05% | |
44 Neutral | AU$42.14M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$63.14M | -6.64 | -59.96% | ― | ― | ― | |
42 Neutral | AU$29.26M | -3.13 | -1009.84% | ― | 25.98% | 22.10% |
* Healthcare Sector Average
AU:SHG
Singular Health Group Ltd
0.20
-0.03
-13.04%
AU:M7T
Mach7 Technologies
0.26
-0.10
-28.17%
AU:BMT
Beamtree Holdings Ltd
0.15
-0.11
-42.00%
AU:ALC
Alcidion Group Limited
0.10
0.02
21.25%
AU:PCK
PainChek Ltd
0.14
-0.18
-56.25%
Singular Health Group Ltd Corporate Events
Singular Health Director Increases Direct Shareholding via On-Market Purchase
Mar 23, 2026
Singular Health Group has disclosed a change in director Howard Digby’s interests in the company’s securities, following an on-market purchase of additional ordinary fully paid shares. Digby acquired 41,666 shares for $10,000, increasi...
Singular Health Accelerates U.S. Rollout and Regulatory Wins as Imaging Platform Gains Traction
Jan 26, 2026
Singular Health Group reported a quarter of strong operational progress, highlighted by the continued rollout of its Provider Network Solution (PNS) contract in the U.S., where deployment of an additional 500 3DICOM MD licences is underway and tri...
Singular Health Raises $344,000 From Option Exercise, Issues Escrowed Shares
Jan 20, 2026
Singular Health Group Limited has raised $344,000 through the exercise of 1,720,000 unlisted options at $0.20 each, resulting in the issuance of an equivalent number of fully paid ordinary shares. The newly issued shares will be subject to a 12...
Singular Health Seeks ASX Quotation for 1.72 Million New Shares
Jan 20, 2026
Singular Health Group Ltd has applied to the ASX for quotation of 1,720,000 new fully paid ordinary shares, issued on 19 January 2026, following the exercise of options or conversion of other securities. The additional share quotation modestly exp...
Singular Health Wins Rapid FDA Clearance for Cloud-Based 3D Imaging Platform
Jan 12, 2026
Singular Health Group has secured U.S. FDA 510(k) clearance for 3DICOM MD Cloud, a Class II Software as a Medical Device and cloud-based evolution of its previously cleared 3DICOM MD desktop software, allowing the company to market and deploy the ...
Singular Health Options Lapse as 5 Million SHGAY Securities Expire Unexercised
Jan 7, 2026
Singular Health Group Ltd has announced the cessation of 5,000,000 listed options (ASX code SHGAY) that expired unexercised on 23 December 2025, each carrying an exercise price of A$0.40. The lapse of these options slightly simplifies the company&...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.